Introduction
Mechanism of action
Why is CDK4/6 inhibition reasonable in luminal breast cancer?
Clinical data
Drug
|
Company
|
Phase
|
---|---|---|
Abemaciclib (LY2835219) | Lilly Oncology | III ongoing (MONARCH trials) |
Ribociclib (LEE011) | Novartis | III ongoing (MONALEESA trials) |
Palbociclib (PD0332991) | Pfizer | III ongoing (PALOMA trials) II and III published |
Efficacy
Safety
Palbociclib + Fulvestrant (
n = 345)
|
Placebo + Fulvestrant (
n = 172)
| |||||
---|---|---|---|---|---|---|
All in % | Grade 3 in % | Grade 4 in% | All in % | Grade 3 in % | Grade 4 in % | |
Neutropenia | 79 | 53 | 9 | 4 | – | <1 |
Leukopenia | 46 | 25 | <1 | 4 | – | <1 |
Anemia | 26 | 3 | – | 10 | 2 | – |
Thrombocytopenia | 19 | 2 | <1 | – | – | – |
Fatigue | 38 | 2 | – | 27 | 1 | – |
Nausea | 29 | – | – | 26 | <1 | – |
Headache | 21 | <1 | – | 17 | – | – |
Upper respiratory infection | 19 | <1 | – | 16 | – | – |
Diarrhea | 19 | – | – | 17 | <1 | – |
Constipation | 17 | – | – | 14 | – | – |
Alopecia | 15 | – | – | 6 | – | – |